Full Fed. Circ. Won't Rehear Actelion Spinoff's Patent Term Bid

Law360 (July 29, 2020, 6:32 PM EDT) -- The full Federal Circuit has refused to revisit its decision that a company spun off from Actelion Pharmaceuticals Ltd. when it was purchased by Johnson & Johnson can't get 99 days added to the term of a patent to make up for delays at the U.S. Patent and Trademark Office.

In a nonprecedential order Tuesday, the full appeals court denied a petition for rehearing filed by Idorsia Pharmaceuticals Ltd., in which it argued that a panel in May wrongly ruled that it was not entitled to add an extra 99 days to a 311-day patent term, as the drugmaker requested....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!